RYVU Therapeutics S.A.
Clinical-stage drug discovery company developing novel small molecule therapies for oncology.
RVU | WAR
Overview
Corporate Details
- ISIN(s):
- PLSELVT00013 (+2 more)
- LEI:
- 2594003WO9Q9HHAFL031
- Country:
- Poland
- Address:
- Kraków Leona Henryka Sternbacha 2, 30-394 Kraków
- Website:
- https://ryvu.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. The company's mission is to develop innovative cancer treatments by targeting key biological pathways, including kinase, synthetic lethality, and immuno-oncology. Its pipeline features multiple candidates advancing through preclinical and clinical stages, such as RVU120 for hematological malignancies and myelofibrosis, and Dapolsertib for lymphoma. Founded in 2007 (formerly as Selvita S.A.), Ryvu leverages its scientific expertise to create precise therapies aimed at improving patient outcomes and quality of life.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-25 16:00 |
Report Publication Announcement
Terminy przekazywania raportów okresowych w 2026 roku / Publication dates for p…
|
English | 1.3 KB | ||
| 2025-11-25 16:00 |
Report Publication Announcement
Terminy przekazywania raportów okresowych w 2026 roku / Publication dates for p…
|
Polish | 903 bytes | ||
| 2025-11-20 17:09 |
Quarterly Report
Sprawozdanie Zarządu Q3 2025 EN
|
English | 4.1 MB | ||
| 2025-11-20 17:09 |
Regulatory News Service
Sprawozdanie Zarządu Q3 2025 PL
|
Polish | 3.8 MB | ||
| 2025-11-20 17:09 |
Interim Report
Sprawozdanie Finansowe Q3 2025 PL
|
Polish | 4.4 MB | ||
| 2025-11-20 17:09 |
Regulatory News Service
Sprawozdanie Finansowe Q3 2025 ENG
|
Polish | 4.3 MB | ||
| 2025-11-03 15:15 |
Regulatory News Service
Prezentacja danych dotyczących romacyklibu (RVU120) oraz dapolsertibu (MEN1703…
|
English | 8.1 KB | ||
| 2025-11-03 15:15 |
Regulatory News Service
Prezentacja danych dotyczących romacyklibu (RVU120) oraz dapolsertibu (MEN1703…
|
Polish | 8.8 KB | ||
| 2025-10-24 19:21 |
Regulatory News Service
Dane przedkliniczne z programu RVU305 (inhibitor PRMT5) oraz platformy ONCOPrim…
|
English | 4.7 KB | ||
| 2025-10-24 19:21 |
Regulatory News Service
Dane przedkliniczne z programu RVU305 (inhibitor PRMT5) oraz platformy ONCOPrim…
|
Polish | 5.1 KB | ||
| 2025-09-18 17:03 |
Audit Report / Information
Raport biegłego z przeglądu śródrocznego sprawozdania finansowego Ryvu Therapeu…
|
English | 154.9 KB | ||
| 2025-09-18 17:03 |
Audit Report / Information
Raport biegłego z przeglądu śródrocznego sprawozdania finansowego Ryvu Therapeu…
|
Polish | 159.6 KB | ||
| 2025-09-18 17:03 |
Interim Report
Sprawozdanie Finansowe Ryvu Therapeutics S.A. H1 2025 ENG
|
English | 4.4 MB | ||
| 2025-09-18 17:03 |
Interim Report
Sprawozdanie Zarządu Ryvu Therapeutics S.A. z działalności H1 2025 ENG
|
English | 3.8 MB | ||
| 2025-09-18 17:03 |
Regulatory News Service
Sprawozdanie Finansowe Ryvu Therapeutics S.A. H1 2025 PL xades
|
Polish | 75.0 KB |
Automate Your Workflow. Get a real-time feed of all RYVU Therapeutics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for RYVU Therapeutics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for RYVU Therapeutics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
